FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Hutchinson Smoking Prevention Project

Phase 3

Completed

Conditions: Smoking Among Youth

Interventions: Behavioral: Social-influences

First Posted Date: 2005-06-27

Last Posted Date: 2012-11-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 8388

Registration Number: NCT00115869

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Hutchinson Study of High School Smoking

Phase 3

Completed

Conditions: Smoking Cessation

Interventions: Behavioral: MI + CBST

First Posted Date: 2005-06-27

Last Posted Date: 2016-05-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2151

Registration Number: NCT00115882

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2005-06-03

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00112567

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

Not Applicable

Completed

Conditions: Acute Undifferentiated Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
AIDS-related Immunoblastic Large Cell Lymphoma
Childhood Acute Lymphoblastic Leukemia in Remission
Childhood Immunoblastic Large Cell Lymphoma
Childhood Myelodysplastic Syndromes
Childhood Nasal Type Extranodal NK/T-cell Lymphoma
Chronic Neutrophilic Leukemia

Interventions: Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: peripheral blood stem cell transplantation
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: laboratory biomarker analysis

First Posted Date: 2005-06-03

Last Posted Date: 2017-05-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00112593

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Splenic Marginal Zone Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma

Interventions: Drug: fludarabine phosphate
Procedure: peripheral blood stem cell transplantation
Radiation: iodine I 131 tositumomab
Other: laboratory biomarker analysis
Other: flow cytometry
Genetic: polymerase chain reaction

First Posted Date: 2005-05-04

Last Posted Date: 2014-08-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 38

Registration Number: NCT00110071

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2005-05-04

Last Posted Date: 2011-11-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00110058

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2005-04-06

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00107523

Locations: 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndromes

First Posted Date: 2005-04-06

Last Posted Date: 2010-09-20

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00107354

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Stage III Small Lymphocytic Lymphoma
Stage IV Small Lymphocytic Lymphoma
Prolymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Stage IV Chronic Lymphocytic Leukemia
T-Cell Large Granular Lymphocyte Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Biological: Rituximab
Radiation: Total-Body Irradiation

First Posted Date: 2005-03-04

Last Posted Date: 2019-07-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 66

Registration Number: NCT00104858

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇩🇰
Rigshospitalet University Hospital, Copenhagen, Denmark
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 2 locations

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Phase 2

Completed

Conditions: Previously Treated Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Waldenstrom Macroglobulinemia
Childhood Myelodysplastic Syndrome
Stage II Contiguous Adult Diffuse Large Cell Lymphoma
Stage II Contiguous Adult Lymphoblastic Lymphoma
Stage II Grade 1 Contiguous Follicular Lymphoma
Stage II Grade 2 Contiguous Follicular Lymphoma
Stage II Non-Contiguous Adult Burkitt Lymphoma

Interventions: Drug: Fludarabine Phosphate
Radiation: Total-Body Irradiation
Procedure: Peripheral Blood Stem Cell Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: Sirolimus

First Posted Date: 2005-03-04

Last Posted Date: 2019-10-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 210

Registration Number: NCT00105001

Locations: 🇩🇰
Rigshospitalet University Hospital, Copenhagen, Denmark
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇩🇪
Medizinische Univ Klinik Koln, Koln, Germany

and more 8 locations

Home Terms & Conditions Privacy Policy